Portfolio Companies News
December 9, 2019The Quinze-Vingts Hospital and GenS...
Paris, France, December 9, 2019, 7.30 am CET – The National Eye Hospital (CHNO) of the Quinze-Vingts in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal... read more
December 9, 2019BONESUPPORTTM CERTiFy STUDY ON CERA...
Lund, Sweden, 08:45 CET, December 9 2019 BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone injuries, today announced the publication of the Level I clinical study CERTiFy in the highly ranked Journal of Bone and Joint Surgery. The authors concluded that CERAMENT® BVF w... read more
December 8, 2019Oncopeptides presents promising dat...
STOCKHOLM — December 8, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In the data presented, melflufen and dexamethasone demonstrated positive efficacy in combi... read more
December 6, 2019Oncopeptides will host a webcast on...
Stockholm – December 6, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10th, 2019, at 13:00 (CET) to provide an update regarding the data presented December 7-8 at the American Society Hematology (ASH) Annual Mee... read more
December 4, 2019Nordic Nanovector: New preclinical ...
Oslo, Norway, 4 December 2019 Nordic Nanovector ASA (OSE: NANO) announces that new data from preclinical studies investigating the effect of Betalutin® (177Lu-lilotomab satetraxetan) on non-Hodgkin's lymphoma (NHL) cell lines will be presented in a poster at the 61st American Society of H... read more
October 31, 2019Q3 2019 General Market Overview
Since the start in 1996, HealthCap funds have invested in 114 portfolio companies.
43 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.